Key terms
About MGNX
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MGNX news
Apr 12
6:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Apr 08
4:00am ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)
Apr 04
7:16am ET
Buy Rating Affirmed for MacroGenics on Strong Safety Profile and Anticipated Efficacy Data
Apr 04
4:35am ET
Barclays Sticks to Its Buy Rating for MacroGenics (MGNX)
Apr 03
7:25pm ET
Positive Outlook for MacroGenics: Buy Rating Affirmed Amid Vobra-duo Developments
Apr 03
4:50pm ET
MacroGenics shares volatile post update on Tamarack and upcoming ASCO meeting
Apr 03
4:38pm ET
MacroGenics says Tamarack data will not be presented at ASCO annual meeting
Mar 14
4:04am ET
The Potential of MacroGenics’ (NASDAQ:MGNX) Pipeline is Driving the Stock
Mar 11
6:22am ET
MacroGenics price target raised to $22 from $16 at JMP Securities
Mar 11
6:13am ET
MacroGenics price target raised to $16 from $14 at H.C. Wainwright
Mar 11
2:32am ET
3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts
Mar 11
12:48am ET
Maintaining Market Outperform for MacroGenics with Increased Confidence in ADC Leadership and Clinical Prospects
Mar 11
12:45am ET
Buy Rating Affirmed for MacroGenics on Promising Pipeline and Strong Financials
Mar 10
6:37pm ET
MacroGenics price target raised to $25 from $13 at Citi
Mar 10
5:31pm ET
Analysts Are Bullish on These Healthcare Stocks: MacroGenics (MGNX), Irhythm Technologies (IRTC)
Mar 08
10:08am ET
MacroGenics price target raised to $24 from $18 at BMO Capital
Mar 08
9:19am ET
MacroGenics price target raised to $29 from $17 at Stifel
Mar 08
5:31am ET
MacroGenics price target raised to $25 from $23 at Barclays
Mar 08
3:46am ET
MacroGenics (MGNX) Receives a Buy from Barclays
Mar 07
4:23pm ET
MacroGenics reports FY23 EPS (15c) , consensus 37c
Mar 06
7:37am ET
TD Cowen Remains a Hold on MacroGenics (MGNX)
Mar 04
7:12am ET
MacroGenics price target raised to $24 from $12 at BTIG
Feb 29
5:47am ET
MacroGenics price target raised to $23 from $12 at Barclays
Feb 29
2:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX)
Feb 14
6:09am ET
MacroGenics downgraded to Neutral from Buy at H.C. Wainwright
Jan 24
4:47pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 24
7:20am ET
MacroGenics price target raised to $16 from $10 at JMP Securities
Jan 22
10:57am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for MGNX
MGNX Financials
Key terms
Ad Feedback
MGNX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MGNX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
